secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2025-09-30T23:59:59+00:00
Accession:  0001493152-25-016210
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine LPCN 1154 Phase 3 PPD trial: 1/3 randomized; topline 2Q26; DSMB review 4Q25
--------------------------------------------------------------------------------

- One-third of planned patients randomized in LPCN 1154 Phase 3 trial for postpartum depression.
- Topline results expected in second quarter 2026.
- Independent DSMB safety review planned for fourth quarter 2025; update post-DSMB.
- Trial conducted entirely outpatient; no medical monitoring by HCP required per FDA feedback.
- CEO Mahesh Patel states LPCN 1154 can become standard of care; 505(b)(2) NDA submission targeted in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000149315225016210/0001493152-25-016210-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000149315225016210/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-016210

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer